

November 4, 2017

| | |
|---|---|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI - 400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI - 400 001 Company Code No. 524804 |
|---|---|

Dear Sir,

Sub: Analyst / Investor Call


Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we inform you that an Analyst / Investor call on the Un-audited Financial Results of the Company for the second quarter and half year ended 30th September, 2017 is scheduled on Friday, 10th November, 2017 at 08:30 am.

Please find attached the dial-in details of the call.

We request you to take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary



4th Nov 2017, Hyderabad, India

Aurobindo Pharma Limited Q2 FY17-18 earnings call is scheduled on 10th Nov 2017 at 8:30 AM

The dial-in details to participate in the call is as under. You may also pre-register in the call through the link mentioned below.

| | |
|---|--|
| Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you are connected to your call in time. | |
| Primary Number: | +91 22 3960 0689 |
| <i>The number listed above are universally accessible from all networks and all countries.</i> | |
| Local Access Number: | 3940 3977 Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune <i>Accessible from all carriers.</i> |
| Toll Free Number: | USA : 1866 746 2133 UK : 0808 101 1573 Singapore : 800 101 2045 Hong Kong : 800 964 448 |
| Pre-register Link | URL: http://services.choruscall.in/diamondpass/registration?confirmationNumber=8047377 |

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Krishna Kiran
Investor Relations,
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

